Medprin Regenerative Medical Technologies Co (SZSE:301033) Total Receivables: ¥29.0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SZSE:301033 Medprin Regenerative Medical Technologies Co Ltd SZSE:301033
78 GF Score
Price ¥53.02
GF Value ¥73.38
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Medprin Regenerative Medical Technologies Co Total Receivables?

Medprin Regenerative Medical Technologies Co SZSE:301033 +0.11% 78 Total Receivables is ¥29.0 Mil as of Jun. 2026. GuruFocus rates SZSE:301033 with a GF Score™ of 78/100 and a GF Value™ of ¥73.38 (Modestly Undervalued). The stock has 1 warning sign investors should review.

Medprin Regenerative Medical Technologies Co's Total Receivables for the quarter that ended in Jun. 2026 was ¥29.0 Mil.

Medprin Regenerative Medical Technologies Co Total Receivables Related Terms

Medprin Regenerative Medical Technologies Co Total Receivables Historical Data

* Premium members only.

The historical data trend for Medprin Regenerative Medical Technologies Co's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medprin Regenerative Medical Technologies Co Total Receivables Chart

Medprin Regenerative Medical Technologies Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial 7.34 11.83 19.44 25.44 26.59

Medprin Regenerative Medical Technologies Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.66 17.94 26.59 21.35 29.01
SZSE:301033
78GF Score
Medprin Regenerative Medical Technologies Co Ltd SZSE:301033
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medprin Regenerative Medical Technologies Co Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of ¥29.0 Mil mean?
Medprin Regenerative Medical Technologies Co (SZSE:301033) has a Total Receivables of ¥29.0 Mil as of Jun. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Medprin Regenerative Medical Technologies Co and its competitors.
Is Medprin Regenerative Medical Technologies Co's Total Receivables too high?
Medprin Regenerative Medical Technologies Co's current Total Receivables is ¥29.0 Mil. Overall, Medprin Regenerative Medical Technologies Co has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medprin Regenerative Medical Technologies Co's Total Receivables compare to ABT and SYK?
Medprin Regenerative Medical Technologies Co's Total Receivables of ¥29.0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Medical Devices & Instruments company?
A good Total Receivables depends on the Medical Devices & Instruments industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Medprin Regenerative Medical Technologies Co and its competitors. Medprin Regenerative Medical Technologies Co's current Total Receivables is ¥29.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medprin Regenerative Medical Technologies Co stock overvalued right now?
Based on GuruFocus' analysis, Medprin Regenerative Medical Technologies Co (SZSE:301033) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥73.38, compared to a current price of ¥53.02 — trading 27.7% below its estimated fair value. The current Total Receivables is ¥29.0 Mil. Medprin Regenerative Medical Technologies Co's overall GF Score™ is 78/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Medprin Regenerative Medical Technologies Co (SZSE:301033), the current Total Receivables is ¥29.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medprin Regenerative Medical Technologies Co (SZSE:301033) Overvalued in 2026?

Based on GuruFocus' analysis, Medprin Regenerative Medical Technologies Co stock appears to be undervalued. The current stock price of ¥53.02 is trading 27.7% below its estimated GF Value™ of ¥73.38. GuruFocus considers Medprin Regenerative Medical Technologies Co to be Modestly Undervalued.

Key valuation signals for SZSE:301033:

  • Total Receivables: ¥29.0 Mil
  • GF Value™: ¥73.38 vs. price of ¥53.02 (27.7% below fair value)
  • GF Score™: 78/100 with 1 warning sign

No single metric tells the full story. See the SZSE:301033 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medprin Regenerative Medical Technologies Co Business Description

Address No. 80 Lanyue Road, 3rd Floor, Area E, High-tech Industrial Development Zone, Guangdong Province, Science City, Guangzhou, CHN, 510700
Medprin Regenerative Medical Technologies Co Ltd is engaged in the development and manufacturing of high-performance implanted medical devices.
78GF Score

Get the complete analysis for SZSE:301033

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥53.02
Price
¥73.38
GF Value